Current Progress and Future Directions for Tau-Based Fluid Biomarker Diagnostics in Alzheimer’s Disease

Current Progress and Future Directions for Tau-Based Fluid Biomarker Diagnostics in Alzheimer’s Disease

Despite continued efforts, there remain no disease-modifying drugs approved by the United States Food and Drug Administration (FDA) or European Medicines Agency (EMA) to combat the global epidemic of Alzheimer’s disease. Currently approved medicines are unable to delay disease progression and are li...

Full description

Bibliographic Details
Main Authors: Mohammad Arastoo, Richard Lofthouse, Lewis K. Penny, Charles R. Harrington, Andy Porter, Claude M. Wischik, Soumya Palliyil
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:International Journal of Molecular Sciences
Subjects:
Alzheimer’s disease
Tau
biomarkers
diagnostics
cerebrospinal fluid
blood
Online Access:https://www.mdpi.com/1422-0067/21/22/8673

Similar Items

Similar Items